Litcius/Paper detail

Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial

Jin Kyun Park, Miriam Kim, Ji In Jung, Ju Yeon Kim, Jeong HeeJin, Jun Won Park, Kevin Winthrop, Eun Bong Lee

2024The Lancet Rheumatology15 citationsDOI

Topics & Concepts

ReactogenicityMedicineImmunogenicitySystemic reactionPlaceboDouble blindSafety profileDermatologyImmunologyInternal medicineAdverse effectAntibodyAllergyAlternative medicinePathologyHerpesvirus Infections and TreatmentsSystemic Lupus Erythematosus ResearchOcular Diseases and Behçet’s Syndrome
Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial | Litcius